BGLC · BioNexus Gene Lab Corp
$1.40
-0.07 (-4.76%)
At close · Sep 2
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management believes that the Company’s existing cash balance, together with its positive working capital position, will provide sufficient liquidity to fund operations and meet its obligations as they become due for at least the next twelve months from the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$4.31M
Shares
2.93M
BGLC metrics
58 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$1.47
Market cap
$4.31M
Price action
19 metricsPrice change (1W)
-5.2%
Price change (30D)
+2.8%
Price change (3M)
-36.1%
Price change (6M)
-41.9%
Price change (YTD)
-62.8%
Price change (1Y)
-74.1%
Trailing year
Price change (5Y)
—
52-week high
$6.00
52-week low
$1.32
Change from 52-week high
-75.5%
Change from 52-week low
+11.4%
Annualized volatility
74.2%
Beta
1.3
RSI (14D)
42.7
Price vs SMA 50
-12.5%
Price vs SMA 200
-43.5%
Avg volume (3M)
94,646
Relative volume
0.0
Average dollar volume
$186,155
Company
3 metricsSector
Basic Materials
Industry
Specialty Chemicals
Shares outstanding
2.93M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 71.5%
P / book
0.6
reciprocal yield 178.0%
FCF yield
-19.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-58.9%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
12.3%
Operating margin
-81.8%
Trailing 12 months
Net margin
-82.4%
Gross profit (TTM)
$385,894
Operating profit (TTM)
−$2.56M
Net income (TTM)
−$2.58M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-27.3%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-96.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.13M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.5%
Year over year · more shares
Revenue CAGR (3Y)
-12.1%
Revenue CAGR (5Y)
-8.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-33.1%
Return on assets
-29.5%
Debt / equity
—
Current ratio
6.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$853,600
Quick ratio
5.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.23M
Latest balance sheet
Cash & equivalents
$1.23M
Total assets
$8.73M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$846,565
Capital expenditures (TTM)
$7,035
R&D (TTM)
$54,132
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
1.7%
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
3
13F filer change QoQ
+1
Institutional ownership
0.5%
Short interest
3 metricsShort interest
0.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
35 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—